ZYXI Stock Overview
Designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.17 |
| 52 Week High | US$13.77 |
| 52 Week Low | US$7.15 |
| Beta | 0.53 |
| 1 Month Change | 4.61% |
| 3 Month Change | -1.92% |
| 1 Year Change | -21.89% |
| 3 Year Change | -14.98% |
| 5 Year Change | 10.27% |
| Change since IPO | 282.43% |
Recent News & Updates
Recent updates
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
Nov 12
Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Oct 26Zynex, Inc.: 2025 Looks Like A Brighter Year
Oct 09With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For
Jul 31Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88
May 03Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Mar 03Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
Jan 24Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?
Aug 03Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Shareholder Returns
| ZYXI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.2% | -3.6% | -4.0% |
| 1Y | -21.9% | 11.2% | 24.0% |
Return vs Industry: ZYXI underperformed the US Medical Equipment industry which returned 12.2% over the past year.
Return vs Market: ZYXI underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| ZYXI volatility | |
|---|---|
| ZYXI Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ZYXI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZYXI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,100 | Thomas Sandgaard | www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI fundamental statistics | |
|---|---|
| Market cap | US$267.50m |
| Earnings (TTM) | US$4.82m |
| Revenue (TTM) | US$193.67m |
53.9x
P/E Ratio1.3x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI income statement (TTM) | |
|---|---|
| Revenue | US$193.67m |
| Cost of Revenue | US$39.34m |
| Gross Profit | US$154.32m |
| Other Expenses | US$149.50m |
| Earnings | US$4.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 79.69% |
| Net Profit Margin | 2.49% |
| Debt/Equity Ratio | 163.0% |
How did ZYXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 08:40 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zynex, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Parth Talsania | Equisights |